Table 4.
Multi-variable Cox regression analyses for OS, PFS, LRRFS, and DMFS.
| Variables | OS |
PFS |
LRRFS |
DMFS |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P | |
| Age | ||||||||
| ≤60 | ref | 0.088 | ||||||
| ＞60 | 1.643 (0.930–2.905) | |||||||
| ECOG PS | ||||||||
| 0 | ref | 0.026 | ref | 0.019 | ref | 0.013 | ||
| 1-2 | 1.756 (1.070–2.881) | 1.718 (1.092–2.701) | 2.042 (1.159–3.596) | |||||
| EBV-DNA | ||||||||
| ＜400 | ref | 0.075 | ref | 0.007 | ref | 0.003 | ||
| ≥400 | 1.519 (0.959–2.408) | 1.803 (1.175–2.768) | 2.229 (1.302–3.814) | |||||
| T stage | ||||||||
| 1-2 | ref | 0.390 | ref | 0.174 | ref | 0.011 | ref | 0.645 |
| 3-4 | 1.257 (0.746–2.117) | 1.394 (0.863–2.250) | 2.637 (1.248–5.569) | 1.149 (0.636–2.077) | ||||
| N stage | ||||||||
| 0-1 | ref | 0.039 | ||||||
| 2-3 | 1.974 (1.036–3.762) | |||||||
| Clinical stage | ref | 0.438 | ||||||
| I-III | ref | 0.596 | ref | 0.799 | 1.247 (0.714–2.179) | |||
| IVa | 1.147 (0.691–1.904) | 1.063 (0.665–1.699) | ||||||
| PIV | ||||||||
| Low | ref | 0.007 | ref | 0.049 | ref | 0.031 | ||
| High | 2.231 (1.241–4.011) | 1.664 (1.003–2.760) | 2.081 (1.071–4.044) | |||||
OS overall survival, PFS progression free survival, LRRFS local regional recurrence free survival, DMFS distant metastasis free survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, PIV pan-immune-inflammation value.